Stay updated with breaking news from ரிச்சி வைட்லோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Somerset, N.J. (PRWEB) August 12, 2021 Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical ....
Subscribe Catalent looks to meet needs of expanding CGT market, completes expansion work at biologics drug substance facility By Jane Byrne Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinical supply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies. The financial outlay has enabled part of the facility to be dedicated to the safe handling of cell and gene therapy (CGT) samples, including the installation of cryogenic storage, allowing biological materials such as cell therapies to be preserved in liquid nitrogen vapor at temperatures of around -180°C, said the CDMO. ....
Sharing the news on Thursday (15 th April), the company said the investment has enabled part of the facility to be dedicated to the safe handling of cell and gene therapy samples, including the installation of cryogenic storage, allowing biological materials to be preserved in liquid nitrogen vapor at temperatures of around -180°C. The facility also has the ability to package, label and distribute cryogenic materials, ensuring the integrity of the therapies being prepared for clinical trials, and has been designed so that capacity can be rapidly expanded further to meet growing clinical supply needs, as well as future commercial demand. ....
Catalent Adds Cryogenic Capabilities at Philadelphia Clinical Supply Services Facility to Meet Growing Demand for Cell and Gene Therapy Development Share Article Catalent, the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies. Establishing robust clinical supply chain services for cell and gene therapies is complex and challenging, and Catalent has undertaken an in-depth strategic review to evaluate how it can establish a safe, efficient and flexible approach to support this fast-growing area of the industry ....